<?xml version="1.0" encoding="UTF-8"?>
<ref id="B2-ijerph-17-04951">
 <label>2.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dore</surname>
    <given-names>G.J.</given-names>
   </name>
   <name>
    <surname>Conway</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Luo</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Janczewska</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Knysz</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Podsadecki</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials</article-title>
  <source>J. Hepatol.</source>
  <year>2016</year>
  <volume>64</volume>
  <fpage>19</fpage>
  <lpage>28</lpage>
  <pub-id pub-id-type="doi">10.1016/j.jhep.2015.08.015</pub-id>
  <?supplied-pmid 26321288?>
  <pub-id pub-id-type="pmid">26321288</pub-id>
 </element-citation>
</ref>
